TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Industry News Articles > Log or not log (transform data) that’s the question

Log or not log (transform data) that’s the question

Log or not log (transform data) that’s the question

By Jean-François Michiels (Senior Manager Statistics and Data Science at Pharmalex), Deniz Akinc (Manager Statistics and Data Science at Pharmalex) and Marieke Verweij (Scientist at Janssen)

 

In the analysis of (bioassay) data, there are assumptions to be validated such as data is expected to be approximately normally distributed with a constant variance across the specified range. Most of the time, the constant variance (homoscedasticity) assumption cannot be satisfied in bioassay data. In case this assumption fails, the estimate of within-assay variance will be unreliable, which will also affect the computation of the overall percent coefficient of variation (%CV). Log transformation is the most common used tool to satisfy these assumptions of the analysis, specifically the constant variance assumption.

 

The focus of this article is to demonstrate how the %CV computation changes when performing an analysis with log-transformed data instead of untransformed data. The following example is used to illustrate this effect of log-transformation and how to use JMP to correctly calculate the %CV of transformed data.  

Illustration by cell measurements analysis

A concentrated cell suspension is prepared using the manual counting as the reference. This concentrated cell suspension is then diluted to prepare two additional cell concentration levels. Using the technique to be evaluated, each cell level is measured three times. The whole experiment is repeated on four different days (aka runs).

 

The data structure is shown below.

Table 1. The structure of the data

In order to compute the %CV, the following linear mixed model is fitted to the data;

Y=β_0+β_1*X+a+ε

where

  • Y are the measured and theoretical cell concentration
  • β_0 and β_1 are the intercept and slope of the model, respectively
  • a~N(O,σ_run^2) is the random run effect
  • ε~N(0,σ_^2) is the residual error

From Figure 1, it can be observed that the residuals computed from different cell concentration levels do not have the same variability (i.e. heteroscedasticity).

Figure 1. The plot of predicted values versus residuals with untransformed data.

When the following linear mixed model is fitted to the log-transformed data;

log⁡(Y)=β_0+β_1*log⁡(X)+a+ε,

the residuals have roughly the same variability across the different cell concentration levels, see Figure 2. Some difference in variability between levels can be observed. Nevertheless, those differences are less extreme than the model without log-transformation.

Figure 2. The plot of predicted values versus residuals with log-transformed data.

The second model is preferred because the log transformation of the response (measured cell concentration) corrects the heteroscedasticity of the residuals and the log transformation of the explanatory variable (theoretical cell concentration) is required to obtain a linear trend.

Coefficient of variation after log transformation

The %CV is a unit-less measure of variation. Under normal distribution, it was defined as;

%CV=100%*σ/μ

where

  • σ is the standard deviation
  • μ is the mean

When data were applied a log-transformation, another formula is required to obtain the %CV in the original units. The formula below is provided for a natural-log transformation:

%CV=√(e^(σ^2 )-1)

where

  • e is exponent
  • Log is natural-base log (ln)
  • σ is the standard deviation

The formula below is provided for 10 base-log transformation. The two expressions are mathematically equivalent.

%CV=100%*√(e^([log⁡(10) ]^2*σ^2 )-1)=100%*√(10^(log⁡(10)*σ^2 )-1)

If the formula for normal distribution is used instead of the formula for log-transformed data, an incorrect %CV will be obtained.

 

In addition, the correct formula should be carefully applied as it is prone to errors (such as, use of variance instead of standard deviation or, if the formula for natural-log transformation is used although the data has been log 10-transformed).

Implementation of the formula in JMP

JMP is a statistical software, widely used for its user-friendly interface. In addition, the JMP scripting language allows the creation of add-ins.

By using the “Fit Model” menu in JMP (see in Figure 3), the second model (above) is fitted. Note that the model is fitted by making the log 10 transformation in the data table and not by using the utility in the model dialog.

Figure 3. The screenshot of the “Fit Model” menu in JMP.

The variance components are obtained in Table 2 given in a newly opened result screen. These results can be extracted to a JMP data table by right-clicking on this table.

Table 2. The estimates of Variance components obtained by the second model with log-transformed data.

To compute %CV, one can enter the formula editor and create the above-mentioned formula.

Alternatively, a JMP add-in, as shown in Figure 4, has been implemented to add the formula of %CV in the formula editor. This add-in can be freely downloaded here (bottom of the page).

https://www.pharmalex.com/our-services/custom-software-development/

After downloading the add-in, one can install it by double-clicking on it and click on the menu “Add-Ins” and “Install CV formulas in the formula editor”. This latest step needs to be repeated for each JMP session.

 

When editing the formula to obtain the %CV, the formulas are available in the formula editor in a new category named “Pct CV from mixed models”. Formulas are provided for natural log and log 10; and using variance and standard deviation. In addition, in the scripting editor, the description and one example are provided for each of the formula (Figure 4).

Figure 4. The screenshot of %CV computation add-in in JMP.

And if we compute the %CV per concentration level

In the scope of assay validation, %CV is usually provided per concentration level. Using the same tools, the overall %CV can be compared to the %CV per concentration level (Table 3). It can be observed that the %CV are quite different between cell concentration levels, as already noted in the residual plot. if the acceptance criteria were set at %CV < 20% for repeatability and intermediate precision, either per concentration level or in total, the validation of the method would have succeeded.

Table 3. The %CV per concentration level and overall with log-transformed data. In the assay validation terminology, Run, Residual and Total corresponds respectively to between-run, repeatability and intermediate precision.

Conclusions

We have shown that log-transformation is extremely useful for correcting heterogeneity of variances of residuals. Although the %CV under log transformation is not complex, it is easy to make errors, while implementing the formulas. The implementation of the formula in JMP makes the computation of errors less prone to errors. This example demonstrated that JMP is much more than a click-button software, the possibility of scripting analysis is highly valuable.

Contact us now
Related posts
Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Orphan Drug Designation: Securing the Significant Benefits
Orphan Drug Designation: Securing the Significant Benefits
28th March 2022
Virtual Audits: To be, or not to be, that is the question
Virtual Audits: To be, or not to be, that is the question
26th January 2022
Quality Risk Management ICH Q9 – Revision published for public comments
Quality Risk Management ICH Q9 – Revision published for public comments
5th January 2022
Points de vigilance vis-à-vis de la communication institutionnelle en France
Points de vigilance vis-à-vis de la communication institutionnelle en France
23rd November 2021
Search
Upcoming Webinars

May 10th, 2022

Using Real World Evidence to Transform Drug Development and Evaluation: Opportunities and Challenges

04:00 PM CET

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
14h

With a mindful eye on the low environmental impact offered by virtual audits, Kate Coleman investigates the potential for life science companies to continue to benefit from virtual quality and risk auditing techniques.

Read more: https://bit.ly/38g3ADp

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • We couldn’t have asked for a more professional, personable, knowledgeable group of Quality Experts!

    Top 10 Pharma Company, China
    Drug Safety Director
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.





    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for